Albany Molecular Research Inc., of Albany, N.Y., elected Arthur Roth to its board.
Amylin Pharmaceuticals Inc., of San Diego, added Michael Hanley as vice president, discovery research.
Antares Pharma Inc., of Exton, Pa., added Anton Gueth and Thomas Garrity to its board.
Antigenics Inc., of New York, added Renu Gupta as senior vice president of development. Also, Elma Hawkins will become senior adviser to the CEO April 1.
Bayhill Therapeutics Inc., of Palo Alto, Calif., added Frank Valone as vice president of medical affairs.
Biomira Inc., of Edmonton, Alberta, promoted Ronald Helmhold to vice president, treasury and financial operations.
Cambridge Antibody Technology Group plc, of Cambridge, UK, added Catherine Connolly as vice president of human resources and Kathy Lambert as vice president, quality.
Cortex Pharmaceuticals Inc., of Irvine, Calif., appointed Peter Drake to its board.
Curis Inc., of Cambridge, Mass., appointed Kenneth Kaitin to its board.
Delex Therapeutics Inc., of Mississauga, Ontario, appointed David Howard to its board.
Exelixis Inc., of South San Francisco, said Frank McCormick will assume a senior advisory role in the research and development organization at the end of the year, replacing R&D President and Chief Scientific Officer Geoffrey Duyk, who is leaving.
Favrille Inc., of San Diego, appointed Michael Eagle to its board and Daniel Gold chief scientific officer.
Fleishman-Hillard in Atlanta added Mike Greenwell as senior vice president.
Genaera Corp., of Plymouth Meeting, Pa., added John Armstrong as executive vice president, responsible for manufacturing.
Generex Biotechnology Corp., of Toronto, said its Antigen Express subsidiary appointed Eric von Hofe vice president of technology development.
Genstruct Inc., of Cambridge, Mass., appointed Sharan Pagano vice president, business development and alliances.
Hemispherx Biopharma Inc., of Philadelphia, appointed Luc Montagnier to its scientific advisory board.
Idenix Pharmaceuticals Inc., of Cambridge, Mass., is adding Charles Cramb to its board.
Iliad Chemicals Pty Ltd., of Melbourne, Australia, appointed Gino Vairo head of drug discovery and development.
Immuno-Designed Molecules, of Paris, added Kerry Segal as vice president, business development.
Invitrogen Corp., of Carlsbad, Calif., appointed Joseph Rodriguez senior vice president of human resources.
MIV Therapeutics Inc., of Vancouver, British Columbia, added Arun Chockalingam as special adviser on scientific and international affairs.
Nordic Biotech Advisors, the advisory company for Nordic Biotech K/S, a biotech investment fund, added Ichiro Shinkai to its affiliated advisory group.
Nova BioGenetics Inc., of Atlanta, named Todd Smith secretary and treasurer.
Palatin Technologies Inc., of Cranbury, N.J., said its executive vice president of research and development, Perry Molinoff, was appointed University of Pennsylvania vice provost for research.
Paratek Pharmaceuticals Inc., of Boston, appointed Sean Johnston vice president, manufacturing operations, and Robert Arbeit executive director for clinical research.
Prestwick Pharmaceuticals Inc., of Washington, appointed Mark Van Ausdal general counsel and vice president, business development.